home / stock / achv / achv news

ACHV News and Press, Achieve Life Sciences Inc. From 01/28/22

Stock Information
Company Name: Achieve Life Sciences Inc.
Stock Symbol: ACHV
Market: NASDAQ
Website: achievelifesciences.com
Menu
ACHV ACHV Quote ACHV Short ACHV News ACHV Articles ACHV Message Board
Get ACHV Alerts

News, Short Squeeze, Breakout and More Instantly...
ACHV - 36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022

RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8 th - 11 th , 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The vir...
ACHV - Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

SEATTLE and VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today annou...

ACHV - Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference

SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Ch...

ACHV - Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation

SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, t...
ACHV - Achieve Life secures $25M loan facility to fund cytisinicline smoking cessation program

Achieve Life Sciences (ACHV +2.2%) has entered into a $25M debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. The proceeds and funds are expected to fund the completion of the cytisinicline smoking cessation clinical development program. As part of the contingen...

ACHV - Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Development

SEATTLE and VANCOUVER, British Columbia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today annou...

ACHV - Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today...
ACHV - Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today...

ACHV - Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q3 2021 Results - Earnings Call Transcript

Achieve Life Sciences, Inc. (ACHV) Q3 2021 Earnings Conference Call November 9, 2021, 04:30 PM ET Company Participants Jaime Xinos - EVP, Commercial John Bencich - CEO & Director Jerry Wan - Principal Accounting Officer Cindy Jacobs - President, Chief Medical Officer & Director Confer...

ACHV - Achieve Life Sciences EPS beats by $0.40

Achieve Life Sciences (NASDAQ:ACHV): Q3 GAAP EPS of -$0.71 beats by $0.40. As of September 30, 2021, Achieve’s cash equivalents, and restricted cash was $33.4 million.  Press Release For further details see: Achieve Life Sciences EPS beats by $0.40

Previous 10 Next 10